TISSEEL Ready to use Solutions for Sealant

Supportive treatment where standard surgical techniques are insufficient

- for improvement of haemostasis (see section 5.1)

- as a tissue glue to promote adhesion/sealing or as suture support:

  - in gastrointestinal anastomoses

  - in neurosurgery where contact with cerebro-spinal fluid or dura mater may occur

For mesh fixation in hernia repair, as an alternative or adjunct to sutures or staples.

TISSEEL is for topical (i.e., epilesional) use only, do not inject.

TISSEEL must not be applied intravascularly (see Section 4.4).

The use of TISSEEL is restricted to experienced surgeons who have been trained in the use of TISSEEL.

Posology

The amount of TISSEEL Ready to use to be applied and the frequency of application should always be oriented towards the underlying clinical needs for the patient.

The dose to be applied is governed by variables including, but not limited to, the type of surgical intervention, the size of the area and the mode of intended application, and the number of applications.

To avoid the formation of excess granulation tissue and to ensure gradual absorption of the solidified fibrin sealant, as thin a layer as possible of TISSEEL Ready to use should be applied (See section 4.4).

If used for tissue adherence, it is recommended that the initial application cover the entire intended application area.

Application of the product must be individualized by the treating physician. In clinical trials, the individual dosages have typically ranged from 4 to 20 ml. For some procedures, larger volumes may be required.

The initial amount of the product to be applied at a chosen anatomic site or target surface area should be sufficient to entirely cover the intended application area.

The application can be repeated, if necessary. However, avoid reapplication of TISSEEL Ready to use to a pre-existing polymerized TISSEEL Ready to use layer as TISSEEL Ready to use will not adhere to a polymerized layer.

As a guideline for the gluing of surfaces, 1 pack of TISSEEL Ready to use 2 ml (i.e. 1 ml Sealer Protein Solution plus 1 ml Thrombin Solution) will be sufficient for an area of at least 10 cm².

When TISSEEL Ready to use is applied by spraying, the same quantity will be sufficient to coat considerably larger areas, depending on the specific indication and the individual case.

When TISSEEL Ready to use is used for mesh fixation it may be applied as drops and/or by a spray technique depending on the preference of the surgeon. Usually the drops of TISSEEL are applied where surgeons routinely position staples and the layer of fibrin sealant achieved with spraying allows the entire mesh to be fixed in place without shrinking and folding.

The quantity of TISSEEL Ready to use required for mesh fixation depends on the mesh size selected and the recommended amount is the same for different application techniques. For example, 2-4 ml of reconstituted TISSEEL Ready to use applied as a thin layer is suitable to adequately fix a standard size mesh of approximately 10 x 15 cm.

When using the drop technique surgeons should apply TISSEEL Ready to use at key anchor points for fixing the mesh (e.g. pubic tubercle in inguinal hernia repair) and at the margins of the mesh. Application by spray, either alone or in combination with drops, should cover the mesh uniformly with a thin layer.

In inguinal hernia repair the mesh covering vascular structures and nerves can be fixed with TISSEEL Ready to use alone using drops and/or spray.

Paediatric population

Safety and efficacy of the product in paediatric patients have not been established.

Method and route of administration

For topical (i.e. epilesional) use only, do not inject.

Prior to application, TISSEEL must be warmed to 33-37°C. Tisseel must not be exposed to temperatures above 37°C and must not be microwaved.

In order to ensure optimal safe use of TISSEEL by spray application the following recommendations should be followed:

In open wound surgery - a pressure regulator device that delivers a maximum pressure of no more than 2.0 bar (29.0 psi) should be used.

In minimally invasive/laparoscopic procedures – a pressure regulator device that delivers a maximum pressure of no more than 1.5 bar (22 psi) and uses carbon dioxide gas only should be used.

Prior to applying TISSEEL the surface area of the wound needs to be dried by standard techniques (e.g. intermittent application of compresses, swabs, use of suction devices).

Do not use pressurized air or gas for drying the site.

TISSEEL must be sprayed only onto application sites that are visible.

TISSEEL should only be reconstituted and administered according to the instructions and with the devices recommended for this product (see section 6.6).

For spray application, see sections 4.4 and 6.6 for specific recommendations on the required pressure and distance from tissue per surgical procedure and length of applicator tips.

Application beyond the intended area should be avoided.

In surgical procedures that require the use of minimal volumes of fibrin sealant, it is recommended to expel and discard the first few drops of product immediately before application, to ensure use of adequate mixed product (see Section 4.4).

After TISSEEL Ready to use has been applied, allow at least 2 minutes to achieve sufficient polymerization. Depending on type of use, the sealed parts may have to be fixed or held in the desired position for this time.

Oxidised cellulose-containing preparations may reduce the efficacy of TISSEEL Ready to use and should not be used as carrier materials (see section 6.2).

It is strongly recommended that every time TISSEEL Ready to use is applied to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.

See Section 6.6 for more detailed instructions.

TISSEEL Ready to use must not be applied intravascularly. Intravascular application of TISSEEL Ready to use may result in life-threatening thromboembolic events.

Known hypersensitivity to any constituents of the product, including aprotinin (see also section 4.4. Warnings).

TISSEEL Ready to use alone is not indicated for the treatment of active or spurting arterial or venous bleeding which is not controlled by conventional surgical techniques.

TISSEEL Ready to use is not indicated to replace skin sutures intended to close surgical wounds.

TISSEEL Ready to use alone is not indicated for the treatment of severe or brisk arterial or venous bleeding which is not controlled by conventional surgical techniques.

For epilesional use only. Do not apply intravascularly. Soft tissue injection of TISSEEL Ready to use carries the risk of an anaphylactoid reaction and / or local tissue damage.

Caution must be used when applying fibrin sealant using pressurized air or gas. (See Section 4.2 and Section 4.8).

Life threatening thromboembolic complications may occur if the preparation is unintentionally applied intravascularly.

Intravascular application can lead to intravascular coagulation and may result in life-threatening thromboembolic events and might increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients.

TISSEEL must be applied with caution to minimize any risk of intravascular application, for example in coronary bypass surgery. Because of the risk of intravascular injection, the product also must not be injected into highly vascularized tissue, such as nasal mucosa.

In two retrospective, non-randomized studies in Coronary Artery Bypass Graft (CABG) surgery, patients that received fibrin sealant showed a statistically significant increased risk of mortality. While these studies could not provide a determination of a causal relationship the increased risk associated with the use of TISSEEL Ready to use in these patients cannot be excluded. Therefore, additional care should be taken to avoid inadvertent intravascular administration of this product.

Injection of Sealer Protein and/or Thrombin Solution carries a risk of anaphylactoid reactions. Intravascular and intraventricular administration carries the additional risk of a thromboembolic complication. Both complications may be life-threatening. Therefore, care should be taken to ensure that Sealer Protein and/or Thrombin Solution are only applied topically.

Caution must be used when applying fibrin sealant using pressurized air or gas.

Any application of pressurized air or gas is associated with a potential risk of air or gas embolism, tissue rupture, or gas entrapment with compression, which may be life-threatening or fatal.

Apply TISSEEL as a thin layer. Excessive clot thickness may negatively interfere with the product's efficacy and the wound healing process.

Life-threatening/fatal air or gas embolism has occurred with the use of spray devices employing a pressure regulator to administer fibrin sealants. This event appears to be related to the use of the spray device at higher than recommended pressures and/or in close proximity to the tissue surface. The risk appears to be higher when fibrin sealants are sprayed with air, as compared to CO₂ and therefore cannot be excluded with TISSEEL when sprayed in open wound surgery.

When applying TISSEEL using a spray device, be sure to use a pressure within the pressure range recommended by the spray device manufacturer (see table in section 6.6 for pressures and distances).

TISSEEL spray application should only be used if it is possible to accurately judge the spray distance as recommended by the manufacturer. Do not spray closer than the recommended distances.

When spraying TISSEEL, changes in blood pressure, pulse, oxygen saturation and end tidal CO₂ should be monitored because of the possibility of occurrence of air or gas embolism (also see section 4.2).

TISSEEL Ready to use must not be used with the EasySpray/Spray set system in enclosed body areas.

Before the administration of TISSEEL Ready to use, care is to be taken that parts of the body outside the designated application area are sufficiently protected/covered to prevent tissue adhesion at undesired sites.

If fibrin sealants are applied in confined spaces, e.g. the brain or the spinal cord, the risk of compressive complications should be taken into account.

As with any protein containing product, allergic type hypersensitivity reactions are possible. Signs of hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. If these symptoms occur, the administration has to be discontinued immediately.

Intravascular application might increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients. Manifestations of hypersensitivity reactions to TISSEEL observed include: bradycardia, tachycardia, hypotension, flushing, bronchospasm, wheezing, dyspnoea, nausea, urticaria, angioedema, pruritus, erythema, paresthesia. Fatal anaphylactic reactions, including anaphylactic shock, have also been reported with TISSEEL (see section 4.8).

At the first sign or symptom of a hypersensitivity reaction, TISSEEL application must be stopped and medical care initiated. Remaining product must be removed from the site of application.

Injection into the nasal mucosa must be avoided, as thromboembolic complications may occur in the area of the arteria ophthalmica.

Injecting TISSEEL Ready to use into tissue carries the risk of local tissue damage.

TISSEEL Ready to use contains synthetic aprotinin, a monomeric polypeptide known to be associated with anaphylactic reactions. Even in the case of strict local application of aprotinin there is a risk of anaphylactic reaction, particularly in the case of previous exposure. Aprotinin is included in TISSEEL for its antifibrinolytic properties. As with other aprotinin-containing products, the use of TISSEEL should be documented in the patient's records, pointing out that TISSEEL contains aprotinin.

As synthetic aprotinin is structurally identical to bovine aprotinin the use of TISSEEL in patients with allergies to bovine proteins should be carefully evaluated.

In case of shock, standard medical treatment for shock should be implemented.

If fibrin sealants are applied in confined spaces, the risk of compressive complications should be taken into account.

Sealer Protein Solution and Thrombin Solution are made from human plasma. The risk of transmitting an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current viral infections, and by inactivating and/or removing viruses.

Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses or other pathogens.

The measures taken are considered effective for enveloped viruses such as HIV, HBV, and HCV, and for the non-enveloped virus HAV.

The measures taken may be of limited value against small non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (foetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anemia).

It is strongly recommended that every time a patient receives a dose of TISSEEL Ready to use, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product. Oxidised cellulose-containing preparations should not be used with TISSEEL Ready to use (See section 6.2 Incompatibilities).

Adequate data are not available to support the use of this product in application through a flexible endoscope for treatment of bleeding or in vascular surgery.

Safety and effectiveness of the product in pediatric patients have not been established as limited clinical study data are available.

No formal interaction studies have been performed. Similar to comparable products or thrombin solutions, the product may be denatured after exposure to solutions containing alcohol, iodine or heavy metals (e.g. antiseptic solutions). Such substances should be removed to the greatest possible extent before applying the product.

The safety of fibrin sealants/haemostatics for use in human pregnancy or breastfeeding has not been established in controlled clinical trials. Experimental animal studies are insufficient to assess the safety with respect to reproduction, development of the embryo or foetus, the course of gestation and peri-and postnatal development.

Therefore, the product should be administered to pregnant and lactating women only if clearly needed.

No undesirable effects during pregnancy and lactation have been reported. See section 4.4 for information on Parvovirus B19 infection.

The effects of TISSEEL Ready to use on fertility have not been established.

Not relevant.

Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the application site, bradycardia, bronchospasm, chills, dyspnoea, flushing, generalized urticaria, headache, hives, hypotension, lethargy, nausea, pruritus, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) may occur in rare cases in patients treated with fibrin sealants / haemostatics.

In isolated cases, these reactions have progressed to severe anaphylaxis. Such reactions may especially be seen, if the preparation is applied repeatedly, or administered to patients known to be hypersensitive to aprotinin (see Section 4.4) or any other constituents of the product.

Even if a second treatment with TISSEEL Ready to use was well tolerated, a subsequent administration of TISSEEL or systemic administration of aprotinin may result in severe anaphylactic reactions.

In the event of hypersensitivity reactions the administration has to be discontinued immediately.

Soft tissue injection of TISSEEL Ready to use carries the risk of an anaphylactoid reaction and / or local tissue damage (see Section 4.4).

Reactions to antibodies against components of fibrin sealant / haemostatic products may occur rarely. Inadvertent intravascular injection could lead to thromboembolic events and disseminated intravascular coagulation, and there is also a risk of anaphylactic reaction (see Section 4.4).

For safety with respect to transmissible agents, see Section 4.4.

The following undesirable effects have been reported from clinical trials investigating the safety and efficacy of TISSEEL and from post-marketing experience with Baxter Fibrin Sealants. In these trials, TISSEEL was administered for adjunct hemostasis in cardiac, vascular, total hip replacement and in liver and spleen surgeries. Other clinical trials included the sealing of lymphatic vessels in patients undergoing axillary lymph node dissection, sealing of colonic anastomosis and in durasealing in the posterior fossa. In these studies a total of 1146 patients were administered Baxter Fibrin sealant.

For the undesirable effects reported from post-marketing experience with Baxter Fibrin Sealants, the frequency cannot be estimated from the available data.

Very common (≥ 1/10)

Common (≥ 1/100 to <1/10)

Uncommon (≥ 1/1,000 to <1/100)

Rare (≥ 1/10,000 to <1/1,000)

Very rare (< 1/10,000)

Not known (cannot be estimated from the available data)

* anaphylactic reactions and anaphylactic shock have included fatal outcomes.

** as a result of intravascular application into the superior petrosal sinus.

*** as with other fibrin sealants life-threatening/fatal air or gas embolism when using devices with pressurized air or gas occurred; this event appears to be related to an inappropriate use of the spray device (e.g. at higher than recommended pressure and in close proximity to the tissue surface.

Class Reactions

Other adverse reactions associated with the fibrin sealant/hemostatic class include: Air or gas embolism when using devices with pressurized air or gas; this event appears to be related to the use of the spray device at higher than recommended pressures and in close proximity to the tissue surface. Manifestations of hypersensitivity include application site irritation, chest discomfort, chills, headache, lethargy, restlessness, and vomiting.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

No case of overdose has been reported.

Pharmacotherapeutic group: local hemostatics, combinations, ATC code: B02BC30; tissue adhesives, ATC code: V03A K

The fibrin adhesion system imitates the last phase of physiological blood coagulation. Conversion of fibrinogen into fibrin occurs by the splitting of fibrinogen into fibrin monomers and fibrinopeptides. The fibrin monomers aggregate and form a fibrin clot. Factor XIIIa, which is generated from factor XIII by the concerted action of thrombin and calcium ions, stabilizes the clot by the cross-linking of fibrin fibres.

As wound healing progresses, increased fibrinolytic activity is induced by plasmin, and decomposition of fibrin to fibrin degradation products is initiated. Proteolytic degradation of fibrin is inhibited by anti-fibrinolytics. Aprotinin is present in TISSEEL Ready to use as an antifibrinolytic to prevent premature degradation of the clot.

Efficacy in haemostasis has been demonstrated in cardiopulmonary surgery, splenic surgery and neurosurgery.

Use as tissue glue to promote adhesion/sealing or as suture support: Efficacy has been demonstrated in surgeries including gastrointestinal anastomoses and neurosurgical procedures where contact with cerebro-spinal fluid or dura mater can occur.

Clinical studies demonstrating haemostasis, sealing, and tissue adhesion were conducted in at least 4,706 patients. These studies were performed in a multitude of surgical specialties, surgical procedures and applications techniques, including but not limited to haemostasis (n=1300), gastrointestinal anastomoses (n=1,114), neurosurgery (n=511).

21 open and comparative clinical studies have also been conducted in 2625 patients to demonstrate the use of TISSEEL in mesh fixation during inguinal, femoral and incisional hernia repair by various open and laparoscopic techniques. TISSEEL was at least as effective as staples, tacks or sutures in mesh fixation during the repair of inguinal or femoral hernia using all the currently favoured surgical techniques.

TISSEEL was at least as effective in repair of incisional hernias when judged by recurrence rates. In addition, the evidence demonstrated that there were no differences in postoperative complications between mesh fixation methods. In several studies the level of postoperative pain was significantly lower in the TISSEEL group.

There is limited experience in children during cardiac surgery (age 4-134 months: n=14).

Fibrin Sealant VH S/D (frozen presentation) was evaluated in a prospective, parallel design, randomized (1:1), double-blind, multicenter clinical study against a previous single virus inactivated formulation of the product, Fibrin Sealant VH (lyophilized presentation), in 317 subjects undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) and median sternotomy. Patients were treated with Fibrin Sealant VH S/D or the control product only when hemostasis was not achieved by conventional surgical methods. For the endpoint, hemostasis achieved at the primary treatment site within 5 minutes of treatment and maintained until closure of the surgical wound, Fibrin Sealant VH S/D was non-inferior to the earlier formulation of the product using a one-sided 97.5% confidence interval on the difference in the proportion of subjects successfully treated.

No difference to control groups not receiving Fibrin Sealant VH S/D was observed in an exploratory study in hip joint replacement for postoperative blood loss and in a study in axillary lymph node dissection for duration of axillary drainage.

Intravascular administration is contraindicated. As a consequence, intravascular pharmacokinetic studies were not performed in man.

Fibrin sealants/hemostatics are metabolized in the same way as endogenous fibrin by fibrinolysis and phagocytosis.

No preclinical safety data are available for Fibrin Sealant VH S/D on subacute and chronic toxicity, carcinogenicity, reproductive and developmental toxicity or immune stimulation.

Single-dose toxicity studies in rats and rabbits indicated no acute toxicity of Fibrin Sealant VH S/D (frozen presentation). There was no evidence of mutagenicity in appropriate in vitro tests.

Fibrin Sealant VH S/D (frozen presentation) was well tolerated in wound healing models in rats and rabbits.

The Sealer Protein Solutions of Fibrin Sealant VH S/D (frozen and lyophilized presentations) were also well tolerated by in vitro human fibroblast cultures demonstrating cellular compatibility and non-cytotoxicity.

Based on a detailed literature review, toxicity of the residual solvent/detergent reagents (see 6.1) on Fibrin Sealant VH S/D can be essentially excluded.

Component 1: Sealer Protein Solution

Human Albumin

L-Histidine

Niacinamide

Polysorbate 80 (Tween 80)

Sodium Citrate Dihydrate

Water for Injections

Component 2: Thrombin Solution

Human Albumin

Sodium Chloride

Water for Injections

Sealer Protein and Thrombin Solutions can be denatured following contact with solutions containing alcohol, iodine or heavy metals. Tisseel must not be mixed with other medicinal products.

TISSEEL Ready to use has a shelf life of two years. The expiry date is stated on the package. Shelf life for thawed product see section 6.6.

Store in a freezer (at ≤-20°C).

The cold storage chain must not be interrupted until preparation for use.

Keep TISSEEL Ready to use in the outer carton to protect from light.

The unopened product, thawed at up to 25°C, may be stored at not more than 25°C for up to 72 hours. If the solution is not used within 72 hours after thawing, dispose of TISSEEL

Do not refreeze or refrigerate after thawing.

TISSEEL Ready to use is supplied in a pre-filled single use double chamber syringe (polypropylene) closed with a tip cap packed in two pouches (outer and inner pouch) and one device set with 2 joining pieces and 4 applications cannulas.

TISSEEL Ready to use is available in the following pack sizes of 1 syringe:

  • 2 ml (1 ml of human fibrinogen and 1 ml of human thrombin)

  • 4 ml (2 ml of human fibrinogen and 2 ml of human thrombin)

  • 10 ml (5 ml of human fibrinogen and 5 ml of human thrombin)

Not all pack sizes may be marketed.

Other accessories for application of the product can be obtained from BAXTER.

General

• The inner pouch and its contents are sterile unless the integrity of the outer pouch is compromised.

• The sealer protein and the thrombin solutions should be clear or slightly opalescent.

• Do not use solutions that are cloudy, discolored, have deposits or other changes in their appearance, including the consistency of a solidified gel after thawing.

• Before the application of TISSEEL Ready to use, ensure that all parts of the body outside the desired application area are sufficiently covered to prevent tissue adhesion at undesired sites.

• Some solutions that contain alcohol, iodine or certain types of metals (these are normally found in disinfectants or antiseptics) may reduce the ability of TISSEEL to work normally. These substances should be removed, as far as possible, before TISSEEL Ready to use is applied.

Thawing of the frozen presentation

• Do not use TISSEEL Ready to use unless it is completely thawed and warmed (liquid to slightly viscous consistency).

• TISSEEL Ready to use must not be exposed to temperatures above 37°C and must not be microwaved.

• The protective syringe cap should not be removed until thawing is complete and application tip is ready to be attached.

• To facilitate removal of the tip cap from the syringe, rock the tip cap by moving it backward and forward, then pull the protective cap off the syringe.

Thaw and warm the pre-filled syringes using one of the following options:

Option 1: Quick thawing/warming methods (preparation in a single step)

  a. Sterile Water Bath

  b. Non-Sterile Water Bath

  c. Incubator

Option 2: Thawing at Room Temperature (not above +25°C) followed by warming in Incubator (possibility of interim storage for up to 72 hours at temperatures not exceeding +25°C)

1. Quick thawing/warming methods

An overview of the quick thawing/warming methods is provided in Table 2.

Note: If a water bath is used it must not exceed the temperature of +37°C.

a) Sterile Water Bath (Recommended Method)

• Remove the outer pouch and transfer the pre-filled syringe packed in the inner pouch, into the sterile area.

• Remove the pre-filled syringe from the inner pouch and place the syringe directly into the sterile water heated to 33°C - 37°C ensuring the syringe is completely immersed in the water (See Table 2 for minimum thawing/warming times).

• To monitor the specified temperature range, control the water temperature using a thermometer and change the water as necessary.

b) Non-Sterile Water Bath

• Place the pre-filled syringe packed in both pouches, in a water bath heated to 33°C - 37°C outside the sterile area, ensuring the pouches remain immersed in the water (See Table 2 for minimum thawing/warming times).

• Remove the pouches from the water bath after thawing and warming.

• Dry and remove the outer pouch and transfer the pre-filled syringe in the inner pouch, onto the sterile area.

c) Incubator

• Place the pre-filled syringe, packed in both pouches, in an incubator outside the sterile area (See Table 2 for minimum thawing/warming times).

• After thawing/warming in the incubator, remove the outer pouch and transfer the pre-filled syringe, inside the inner pouch, into the sterile area.

2. Thawing at room temperature (not above 25°C) followed by warming in Incubator

• Thaw the pre-filled syringe, packed in both pouches, at room temperature outside the sterile area (See Table 3 for minimum thawing times).

• Warm the pre-filled syringe, packed in both pouches, in an incubator at 33°C - 37°C outside the sterile area (See Table 3 for minimum warming times).

• After thawing/warming in the incubator, remove the outer pouch and transfer the pre-filled syringe, inside the inner pouch, into the sterile area.

Table 3: Thawing at Room Temperature and Warming in Incubator

Stability after thawing

After thawing and warming at 33°C - 37°C (Options 1 and 2), the product must be used within 12 hours.

After thawing at room temperature (Option 2), the product can be stored for up to 72 hours at temperatures not exceeding 25°C, provided it remains sealed in the original package (both pouches).

Do not re-freeze or refrigerate once thawing has been initiated.

Handling after thawing / before application

To facilitate optimal blending of the two solutions, the two sealant components must be warmed to 33 – 37°C immediately before use (The temperature of 37°C must, however, not be exceeded).

The thawed Sealer Protein Solution should be a slightly viscous liquid. If the solution has the consistency of a solidified gel, it must be assumed to have become denatured (e.g., due to an interruption of the cold storage chain or by overheating during warming). In this case, the TISSEEL Ready to use must not be used.

Non-Spray Administration

For application, connect the double chamber ready-to-use syringe with the sealer protein solution and the thrombin solution to a joining piece and an application cannula – both are provided in the set with the application devices. The common plunger of the double chamber ready-to-use syringe ensures that equal volumes of the two sealant components are fed through the joining piece into the application cannula where they are blended and then applied.

• Expel all air from the syringe prior to attaching any application device.

• Align the joining piece and tether to the side of the syringe with the tether strap hole.

• Connect the nozzles of the double chamber ready-to-use syringe to the joining piece, ensuring that they are firmly attached.

• Attach an application cannula on to the joining piece.

Administration

Prior to applying TISSEEL Ready to use the surface of the wound needs to be dried by standard techniques (e.g. intermittent application of compresses, swabs, use of suction devices). Do not use pressurized air or gas for drying the site.

• Apply the mixed sealer protein - thrombin solution on to the recipient surface or on to the surfaces of the parts to be glued by slowly pressing on the back of the common plunger.

• In surgical procedures that require the use of minimal volumes of fibrin sealant, it is recommended to expel and discard the first few drops of product.

• After TISSEEL Ready to use has been applied, allow at least 2 minutes to achieve sufficient polymerization.

Note: If application is interrupted, clogging occurs immediately in the cannula. Replace the application cannula with a new one only immediately before application is resumed. If the aperture of the joining piece (Y connector) facing the cannula is clogged, use the spare joining piece provided in the package.

After blending of the sealant components, the fibrin sealant starts to set within seconds on account of the high Thrombin concentration (500 IU/ml).

Application is also possible with other accessories supplied by BAXTER that are particularly suited for, e.g. endoscopic use, minimally invasive surgery, application to large or difficult-to-access areas. When using these application devices, strictly follow the Instructions for Use of the devices.

After the two components have been applied, approximate the wound areas. Fix or hold the glued parts with continuous gentle pressure in the desired position to ensure that the setting fibrin sealant adheres firmly to the surrounding tissue.

In certain applications, biocompatible material, such as collagen fleece, is used as a carrier substance or for reinforcement.

Application with Spray Device

When applying TISSEEL using a spray device be sure to use a pressure and a distance from tissue within the ranges recommended by the manufacturer as follows:

When spraying the TISSEEL, changes in blood pressure, pulse, oxygen saturation and end tidal CO₂ should be monitored because of the possibility of occurrence of air or gas embolism (see sections 4.2 and 4.4).

Equivalent spray devices, intended for specific use with TISSEEL, may also be used. When using other spray devices, follow the instructions for use that are provided with the device.

Disposal

Any unused product or waste material should be disposed of in accordance with local requirements.